Type 2 Diabetes Drug Onglyza Linked To Risk Of Heart Failure And Pancreatitis

Posted by Sarah Showard | Apr 08, 2016 | 0 Comments

Type 2 Diabetes Drug Onglyza Linked To Risk Of Heart Failure And Pancreatitis

In 2014, the Food and Drug Administration (FDA) requested clinical trial data from the manufacturer of Type 2 diabetes drugs Onglyza and Kombiglyze XR to review potential heart failure risks. Both drugs are manufactured by AstraZeneca.

It is estimated that approximately 30 million Americans suffer from Type 2 diabetes. Onglyza (saxagliptin) belongs to a class of drugs known as incretin mimetics, which imitate the incretin hormones the body produces to stimulate the release of insulin as part of the digestive process. It works by increasing the level of insulin after meals to reduce blood sugar.

The FDA said that it was reviewing the clinical trial data based on a study published in the New England Journal of Medicine that showed an increased incidence of hospitalization for heart failure among patients on saxagliptin. That study showed a 27% increase in heart failure risk for saxagliptin patients.

A review by the FDA's Endocrinologic and Metabolic Drug Advisory Committee resulted in a recommendation by 14 of the 15 panelists that labeling for Onglyza be updated to include a warning about the potential risks for heart failure. One panelist voted to remove the drug from the market.

Other studies have indicated that Onglyza could increase the risk of chronic pancreatitis, which could lead to pancreatic cancer. In addition, the FDA issued a warning in August 2015 about reported incidents of joint pain in patients taking Onglyza and other Type 2 diabetes drugs that fall into the category of DPP-4 inhibitors.

In October 2015, a lawsuit was filed by a patient's daughter in Illinois alleging that Onglyza caused the death of her mother due to heart failure. Other litigation tied to the use of Onglyza and Kombiglyze XR alleges that AstraZeneca failed to conduct sufficient pre-market trials, failed to warn health care providers and patients about the potential side effects of the drugs and produced fraudulent marketing materials that failed to include information about possible side effects.

Showard Law Firm focuses on helping people who have been injured in accidents or have been the victim of faulty medical products. Contact us to schedule your free consultation with our experienced personal injury legal team for the compassionate representation you deserve.

About the Author

Sarah Showard

Sarah Showard graduated from the University of Maryland in 1985, Magna Cum Laude with a Bachelor of Arts in English-Linguistics and a Certification in Womens Studies. She then graduated from New York University School of Law in 1988. Sarah began practice initially as an insurance defense attorne...


There are no comments for this post. Be the first and Add your Comment below.

Leave a Comment

Showard Law Firm-Tucson's Local Law Firm for defective drug & medical device claims.

Showard 20staff 202017 201026 20special 20edit edit.jpg 20small

Showard Law Firm is dedicated to compassionate representation for our clients who have been injured by defective products, dangerous drugs or the negligence of any individual or company. We are experienced in litigation and ready to ensure you receive the maximum possible settlement for your injuries, medical bills, mental anguish and other losses.

Sarah Showard and Dr. Peter Ott - 2018 Heart Ball Chairs


Sarah and Peter are the proud chairs of this year's Heart and Stroke Ball, held on 2/17/18 at the El Conquistador. With a western theme "Heart of the West", this important fund raiser is in its 60th year, all raising funds to help with research and advances in the case against heart disease in the Tucson community.